This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
P21 (P021)
Synthetic CNTF-derived neurogenic tetrapeptide (Ac-DGGLAG-NH2) with adamantyl modification for BBB penetration — promotes adult hippocampal neurogenesis, upregulates BDNF/TrkB/PI3K/AKT/GSK3β, and s…
Aliases (6)
Overview
What is P21 (P021)?
P21 is a synthetic 11-amino-acid peptide derived from the active region of ciliary neurotrophic factor (CNTF), engineered for greater stability and BBB penetration. It is investigated as a neurogenic and cognition-enhancing agent.
Key Benefits
Reported in preclinical models to enhance hippocampal neurogenesis, cognitive function, and resistance to age-related cognitive decline without the side effects (weight loss, muscle cramps) of full-length CNTF. Anecdotal user reports describe improved memory and mood.
Mechanism of Action
Mimics the active region of CNTF, binding the CNTF receptor complex (CNTFRα/LIFRβ/gp130) and activating JAK/STAT3 and ERK/MAPK signaling. Promotes neural stem cell proliferation and differentiation in the hippocampus and prevents tau pathology in animal models.
Pharmacokinetics
Research Indications
Memory Enhancement
Preclinical studies demonstrate significant improvements in short-term memory, spatial reference memory, and object recognition in normal and diseased mice.
Learning Acceleration
P21 accelerated spatial learning acquisition in water maze tasks, with treated animals showing faster encoding of platform location.
Neurogenesis Promotion
Enhanced proliferation and maturation of newborn neurons in hippocampal dentate gyrus, critical for memory formation.
Alzheimer's Disease
Significantly reduced tau hyperphosphorylation, prevented neurodegeneration, and rescued cognitive deficits in 3xTg-AD mice over 18 months.
Traumatic Brain Injury
Increased newborn neurons by 80%, reversed dendritic/synaptic density loss, and improved memory recall in TBI models.
Age-Related Decline
Restored neurogenesis to levels approaching young adults in aged rats, normalized BDNF/TrkB signaling.
Research Protocols
Disclaimer: These are commonly discussed research protocols and not medical advice.
Peptide Interactions
Both incorporate adamantyl modification; complementary cognitive benefits through different neuropeptide pathways. Per pep-pedia interaction matrix, P21 + Ad…
/ n-acetyl-semax-amidate (NASA) — Compatible per pep-pedia. Different mechanisms (CNTF vs melanocortin) → complementary cognitive benefits. NASA daily intran…
Compatible. Complementary cognitive + anxiolytic effects through different receptor systems.
Compatible. Different mechanisms (neurogenesis vs tissue repair / gut-brain axis). Already in the user's V stack.
Per pep-pedia: "P21 was developed as a defined alternative to Cerebrolysin. Both promote neurogenesis but P21 has defined structure and better BBB penetratio…
Compatible. Complementary mechanisms — NAD+ supports cellular energy metabolism while P21 promotes neurogenesis + synaptic plasticity.
Compatible. Different mechanisms (telomerase / pineal vs neurogenesis).
(all V4) — Synergistic anti-inflammatory + membrane substrate environment that any neurotrophic peptide operates better in.
Per pep-pedia: "Use Caution. Both affect neuroplasticity strongly through different pathways (CNTF/BDNF vs HGF/c-Met) — avoid concurrent use without careful …
(Cerebrolysin, dihexa, multiple BDNF-axis stimulators) — same logic. Pick one neurotrophic intervention per cycle, see what it does, then iterate.
Both modulate GSK3β. Theoretical compound effect; not well-characterized.
Complementary mechanisms - NAD+ supports cellular energy metabolism while P21 promotes neurogenesis and synaptic plasticity
What to Expect
- Week 1Tolerability and dose-response.
- Week 2-4Early effect window.
- Week 4-8Peak benefit assessment.
- Week 8+Cycle decision point.
Side Effects & Safety 6
Side Effects
- 1Injection-site reactions (mild burning, transient erythema) — usually self-limiting <30 min
- 2Occasional mild headache (1–2 hour post-injection)
- 3Mild GI (nausea, occasional)
- 4Mild fatigue or lethargy days 1–3 of cycle
- 5Sleep changes (vivid dreams, occasional insomnia if dosed late)
- 6Mood changes (mild lift or, rarely, mild low mood — variable)
When to Stop
- Allergic reaction / sensitization — synthetic peptide; theoretical risk, no documented anaphylaxis cases in published literature. Watch first 30 minutes of first 3 injections of any cycle (general peptide best practice).
- Aberrant neurogenesis / off-target proliferation — strictly theoretical. No reports, but any compound that drives proliferation in adult tissue carries a non-zero theoretical concern about uncontrolled growth. The 18-month 3xTg-AD safety study showed no adverse effects, which is reassuring but rodent.
- GSK3β inhibition off-target effects — GSK3β is involved in glycogen metabolism, Wnt signaling, circadian rhythm. Chronic systemic GSK3β inhibition (e.g., with lithium) has documented metabolic + thyroid effects. Whether P21's downstream GSK3β modulation rises to that magnitude in humans is unknown.
- Anti-CNTF antibody formation — theoretical, given CNTF-mimetic structure. Not documented in rodent studies but worth monitoring if Phase 2 human data emerges.
- First 30 min of injection #1, #2, #3 of any cycle — general peptide allergy watch
- First 14 days — sensitization developing window
- End of cycle: monitor for any rebound mood / cognitive changes; none reported but poorly characterized
- Active malignancy (theoretical concern about driving proliferation in any tissue)
- Pregnancy / lactation (no data)
- Severe active mood disorder (any neurotrophic intervention can theoretically destabilize mood; conservative practice)
References
P21 Discovery Study (Li et al. 2010, FEBS Letters)
original P21 (Ac-DGGLAG-NH2) demonstrating enhanced learning + memory + neurogenesis in normal C57BL/6 mice
View StudyP021 in 3xTg-AD long-term efficacy (Kazim et al. 2014, Neurobiology of Disease)
chronic oral P021 reduced tau hyperphosphorylation, increased BDNF, rescued cognition
View StudyP21 in TBI mouse model (Chohan et al. 2015, Neuroscience)
controlled cortical impact + Peptide 6 (P21 parent), 80% increase in DG newborn neurons, reversed dendritic + synaptic loss
View StudyP021 prevention of cognitive impairment (Baazaoui & Iqbal 2017, Neurobiology of Aging)
early-stage AD model, prevention of dendritic + synaptic deficits
View StudyComprehensive P021 review (Baazaoui & Iqbal 2022, Biomolecules)
AD therapeutic opportunity, 18-month chronic safety, oral bioavailability, >3h plasma half-life
View StudyP021 in CDKL5 deficiency (Fuchs et al. 2024, J Neurodev Disorders)
in vitro restoration of neuronal deficits, limited in vivo benefit; first published negative datapoint
View StudyCognitive Vitality Assessment of P021 (ADDF, 2025)
Alzheimer's Drug Discovery Foundation independent expert assessment of preclinical efficacy + clinical development status with Phanes Biotech
View Studypep-pedia P21 entry
composition, mechanism, interaction matrix, dosing protocols (community + research-derived)
View StudyCNTF biology + receptor pharmacology (review, Annu Rev Neurosci)
background on the CNTF/CNTFRα/gp130/LIFR receptor complex P21 mimics
View StudyAdamantane modification for BBB penetration (review)
chemistry of adamantyl-tagged peptides for CNS delivery
View StudyCerebrolysin compound file (sibling reference)
for comparison of evidence base + practical positioning
View StudyHow was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.